To assess whether inhibiting CD133 sensitised the tumours to DOX and induced tumour growth regression via MDR1/P-gp in vivo, representative samples from harvested tumour tissues were analysed by WB and IHC for CD133 or P-gp expression, as described previously (Fig. 6e, f). Here, PGP is linked to neoplasm.